Skin cancer

Crop Spraying Drones Market Forecast Report 2023-2028, Featuring Fly Dragon Drone Tech, Prodrone, Parrot Drone, HSE TTA-America, ASTA Technology, Xi'an Wideworldz Aviation Technology & AirBoard

Retrieved on: 
Friday, January 26, 2024
Silicon, Transport, Central State University, University, Research, Farmer, Drone, Melanoma, Federal Aviation Administration, Pesticide, Agriculture, Science, Skin cancer, Crop protection, USDA, Environment, American Farm Bureau Federation, Soybean, Unmanned aerial vehicle, Education, Growth

DUBLIN, Jan. 26, 2024 /PRNewswire/ -- The "Crop Spraying Drones Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 26, 2024 /PRNewswire/ -- The "Crop Spraying Drones Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The crop spraying drones market is experiencing growth driven by rising awareness regarding the detrimental effects of pesticides on the environment and human well-being is a key factor fueling the need for crop spraying drones.
  • In recent years government initiatives have gained momentum, aiming to integrate drone technology into agriculture and boost crop spraying drones market growth.
  • The increasing product launches in the market are pushing the crop spraying drones market in an upward direction.

Lights, Cancer, Action! Sahmyook University Researchers Develop a Light-Responsive Novel Drug Delivery System Against Skin Cancer

Retrieved on: 
Thursday, January 25, 2024
DOX, Nanofiber, Research, Professor, Skin, Heat, Nanorod, DDS, Sahmyook University, Skin cancer, Northern Rail, Camptothecin, Gold, CPT, Journal, Psoriasis, Pharmacotherapy, Health, Motivation, NFS, Pharmaceutical industry

SEOUL, South Korea, Jan. 25, 2024 /PRNewswire/ -- Nanotechnology-based drug delivery systems (DDS) offer several advantages, such as enhanced bioavailability and controlled drug release with reduced dosage. Recently, Sahmyook University researchers have developed a light-responsive DDS to treat skin cancer. By incorporating gold nanorods into the matrix of nanofibers, the study demonstrates external control over the release of anticancer drugs in a sequential and controlled method. This innovative DDS holds promise for future real-life nanotech-based applications in healthcare.

Key Points: 
  • SEOUL, South Korea, Jan. 25, 2024 /PRNewswire/ -- Nanotechnology-based drug delivery systems (DDS) offer several advantages, such as enhanced bioavailability and controlled drug release with reduced dosage.
  • Recently, Sahmyook University researchers have developed a light-responsive DDS to treat skin cancer.
  • In this light, a team of researchers led by Professor Myoung-Hwan Park from Sahmyook University in South Korea has developed a light-responsive nanofiber-based novel drug delivery system (DDS) targeting skin cancer.
  • Accordingly, the integration of nanofibers with on-demand drug delivery systems can open up new possibilities for drug therapy."

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Thursday, January 25, 2024
Patient, Capital market, Karolinska Institute, Electrode, Skin cancer, SCIB, Digital, MBA, CPC, Management

STOCKHOLM, Jan. 25, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 25, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Although the Company has a strategic focus on the USA, Germany continues to be an important and profitable market for SciBase.

CU Anschutz Announces Awardees for the Anschutz Acceleration Initiative

Retrieved on: 
Thursday, January 18, 2024
Pillar, Mortality, Dentures, Dermatology, TIL, Patient, Dementia, Research, Philip Anschutz, Ophthalmology, Health, Geographic atrophy, Skin cancer, Asgari, University, Pharmacology, Chair, Down syndrome, Quality of life, Head, Skin, Dentistry, Disease, Cell, AMD, Doctor of Philosophy, MPH, Gastroenterology, Column, Oncology

AURORA, Colo., Jan. 18, 2024 /PRNewswire/ -- The University of Colorado Anschutz Medical Campus announced the grant awards for the Anschutz Acceleration Initiative, a program focused on advancing cutting-edge healthcare innovations poised to reach patients within three to five years.

Key Points: 
  • The initiative was made possible by a $50 million gift from The Anschutz Foundation , a longtime philanthropic campus partner focused on bringing the innovative work at CU Anschutz to the forefront of patient care.
  • "The Anschutz Foundation has championed the people and programs that drive innovation here," said CU Anschutz Chancellor Donald M. Elliman.
  • The CU Anschutz faculty, whom the Anschutz Acceleration Initiative will fund, represent a range of expertise that spans disciplines including oncology, dermatology, gastroenterology, ophthalmology, pharmacology, dental medicine, and more.
  • To read more about the initiative and the awardees, visit the Anschutz Acceleration Initiative website .

STAGE IV MELANOMA PATIENT RUNNING ACROSS LAKE WINNIPEG TO RAISE FUNDS FOR SKIN CANCER PATIENTS

Retrieved on: 
Wednesday, January 17, 2024
Gimli, Challenge, Skin cancer, Patient, Skin, Melanoma, Transport

Three years after being diagnosed with late stage melanoma and becoming partially paralyzed from the waist down, Chris and Shawn raced each other 30km across frozen Lake Winnipeg and raised almost $20,000 for melanoma patients.

Key Points: 
  • Three years after being diagnosed with late stage melanoma and becoming partially paralyzed from the waist down, Chris and Shawn raced each other 30km across frozen Lake Winnipeg and raised almost $20,000 for melanoma patients.
  • From March 1-3, 2024, Save Your Skin Foundation will host the 5th annual A Viking's Challenge.
  • Since 2021, Chris and Shawn have invited others to participate in-person or virtually in what is now called "A Viking's Challenge".
  • There is a running tally to see how many times participants can "cross" Lake Winnipeg as a group.

Search begins for 2024 America's Top Young Scientist

Retrieved on: 
Tuesday, January 16, 2024
Student, Ellen, Social impact, SCTS, STEM, Science, Skin cancer, Business Insider, Good Morning America, Cancer, Communication, Challenge, TIME, Mobile, Safety, K-12, Creativity, Robotics, Transport, Machine learning, TED (conference), Air pollution, Time (magazine), Discovery, Inc., Public affairs

ST. PAUL, Minn. and CHARLOTTE, N.C., Jan. 16, 2024 /PRNewswire/ -- 3M (@3M) and Discovery Education (@DiscoveryEd) today announced that the 2024 3M Young Scientist Challenge (#YoungScientist) is now open to entries. As the nation's premier middle school science competition, the annual 3M Young Scientist Challenge invites students in grades 5-8 to compete for an exclusive mentorship with a 3M scientist, a $25,000 grand prize, and the chance to earn the title of "America's Top Young Scientist." Competition entries are accepted at YoungScientistLab.com until the deadline on May 2, 2024. 

Key Points: 
  • ST. PAUL, Minn. and CHARLOTTE, N.C., Jan. 16, 2024 /PRNewswire/ -- 3M (@3M) and Discovery Education (@DiscoveryEd) today announced that the 2024 3M Young Scientist Challenge ( #YoungScientist ) is now open to entries.
  • As the nation's premier middle school science competition, the annual 3M Young Scientist Challenge invites students in grades 5-8 to compete for an exclusive mentorship with a 3M scientist, a $25,000 grand prize, and the chance to earn the title of "America's Top Young Scientist."
  • To learn more about the 3M Young Scientist Challenge, including entry details and to find supporting resources, visit youngscientistlab.com .
  • "The 3M Young Scientist Challenge encourages young people to solve everyday problems using science and innovation–and we can't wait to see what you dream up!"

Orlucent Demonstrates Accurate, Non-Invasive Detection in vivo of Melanoma-Related Activity Using First-in-Kind Handheld Mole Imaging System

Retrieved on: 
Tuesday, January 16, 2024
Eye, Dermatology, Research, Melanoma, Scar, Oxygen, Aggression, Skin cancer, Chromatophore, Molecular imaging, Anxiety, FDA, Biopsy, Moles, Melanoma Research, Medical imaging

With the current standard of care, melanoma is identified in suspicious nevi using subjective visual clinical evaluations, during which the color, shape, and size of nevi are assessed using the ABCDE criteria (asymmetry, border, color, diameter, and evolution). When moles exhibit only one or two of these atypical features, discerning whether they could develop into melanoma becomes arduous. To avoid missing a melanoma, dermatologists rely on "when in doubt, cut it out" to manage moles which do not overtly classify as melanoma or benign -- the "grey area" lesions -- resulting in unnecessary biopsies, scarring and patient anxiety.

Key Points: 
  • Melanoma, the most lethal form of skin cancer, has long been a challenge to detect accurately, particularly those cases with the potential for aggressive behavior.
  • When moles exhibit only one or two of these atypical features, discerning whether they could develop into melanoma becomes arduous.
  • Encouraged by these findings, Orlucent is continuing research of mSFI and is preparing for FDA submission.
  • The peer-reviewed article in Pigment Cell and Melanoma Research is titled, "Molecular Skin Fluorescence Imaging: A Tool for Evaluating Early Melanoma Development," and can be found at http://doi.org/10.1111/pcmr.13159 .

Skin Expert Dr. Victoria A. Cirillo-Hyland Joins Exclusive Haute Beauty Network

Retrieved on: 
Friday, January 12, 2024
NBC, Dermatology, CBS, Harvard Medical School, Mohs surgery, Skin cancer, Skin care, ABC, University, Hospital, ELITE, Harvard University, SKIN, CNN, Television

NEW YORK, Jan. 12, 2024 /PRNewswire-PRWeb/ -- Dr. Victoria A. Cirillo-Hyland completed her undergraduate degree at Harvard where she graduated magna cum laude and was a John Harvard Scholar for four years. She attended The University of Pennsylvania School of Medicine where she graduated top of her class. She was an Alpha Omega Alpha Scholar. Dr. Cirillo-Hyland completed her medical internship at The Brigham & Women's Hospital of Harvard Medical School. Dr. Cirillo-Hyland returned to The Hospital of the University of Pennsylvania for her dermatology residency.

Key Points: 
  • Dr. Victoria A. Cirillo-Hyland joins Haute Beauty Network as a skin expert representing the Philadelphia, PA market.
  • She attended The University of Pennsylvania School of Medicine where she graduated top of her class.
  • Together they form the largest and most credentialed dermatology and plastic surgery center to address all of your skin care and aesthetic needs.
  • Dr. Cirillo-Hyland's medical dermatology practice focuses on our most complex cases of skin cancer.

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Tuesday, January 9, 2024
NBC, Capital market, Science, MD, Skin, Karolinska Institute, Health, Rigel, AAD, Skin cancer, George Washington University, ABC, American Academy, SCIB, Worldwide Angel, Clinical, Government, Digital, Strategic planning, MIT, MBA, NYU, Fox, Congress, FDA, American Academy of Dermatology, Subway Series, CNN, Pinnacle, Publication

STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Two external speakers will participate in the event, further supporting the US role in the SciBase strategy going forward.

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Retrieved on: 
Friday, January 5, 2024
Part Two, Skin cancer, Pain, Carcinoma, Patient, Scar, Dermatology, Skin, Therapy, Infection, Part

WEST CHESTER, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the last patient has been dosed in Part 2 of the Company’s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.

Key Points: 
  • “We are pleased to announce that Part 2 of our Phase 2 clinical trial of VP-315 for the treatment of basal cell carcinoma has been fully enrolled and the last patient has been dosed,” said Ted White, Verrica’s President and Chief Executive Officer.
  • “Basal cell carcinoma is the most common form of skin cancer in the U.S. each year and patients are in need of alternative solutions to surgery which can cause pain, infection and scarring.
  • Verrica’s VP-315 program is designed to provide for the targeted delivery of an oncolytic peptide engineered to stimulate the patient’s immune system and destroy cancer cells.
  • Our study remains on track, and we look forward to sharing the data from our Phase 2 clinical trial later this year.”